Key Market Indicators
Sales of Latvian antirheumatic medicine are projected to reach a total of $23 million by 2026. This figure is a rise of 1.9% on the $21 million recorded in 2021. Since 2006, the Latvian market has grown by an average of 5% annually. In 2021, Latvia was the 18th largest market for antirheumatic medicine. Denmark took the top spot with sales of $21 million, followed by Germany, Spain, and Canada.
